Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.
Beatriz Tavares da Silva, Ariana Maia, Maria Teresa Pereira et al.
✦ AI-curated · Sources linked
Case in brief
A pregnant patient with a metastatic neuroendocrine tumor of the ileocecal valve and carcinoid syndrome was treated with lanreotide after undergoing peptide receptor radionuclide therapy and debulking surgery. Throughout the pregnancy, she received lanreotide under multidisciplinary supervision, resulting in no maternal complications and stable disease postpartum. The newborn experienced transient hyperbilirubinemia but developed normally at 18 months.
Diagnostic / clinical pearl
This case underscores the potential for continuing somatostatin analog therapy, such as lanreotide, during pregnancy in selected patients with metastatic neuroendocrine tumors, emphasizing the need for careful monitoring.
Why it matters
The findings contribute to the limited understanding of managing neuroendocrine tumors during pregnancy, particularly regarding the safety and feasibility of ongoing systemic therapies.